Amaurosis Fugax: Clinical Overview
Amaurosis fugax is a transient monocular vision loss lasting typically less than 24 hours (usually minutes) caused by temporary retinal ischemia, and it represents a medical emergency requiring immediate stroke workup because it carries a 2% annual stroke risk and should be managed as a retinal transient ischemic attack 1, 2.
Definition and Clinical Presentation
Amaurosis fugax ("fleeting blindness") presents as:
- Sudden, painless monocular vision loss affecting the entire visual field or portions of it
- Brief duration: typically 1-15 minutes, usually less than 1 hour 2
- Complete resolution without permanent visual deficits
- May be described as a "curtain" or "shade" descending over vision
Important caveat: If the episode is accompanied by periocular pain, consider MOGAD-associated optic neuritis rather than vascular causes 3.
Pathophysiology and Causes
In 95% of cases, amaurosis fugax results from thromboembolic disease 4:
Primary Vascular Etiologies:
- Carotid artery atherosclerosis with embolic phenomena (most common)
- Hemodynamic insufficiency from high-grade carotid stenosis
- Cardiac embolic sources (atrial fibrillation, valvular disease)
- Hypercoagulable states
- Carotid dissection (especially with neck/face pain after trauma)
Less Common Causes:
- Giant cell arteritis (GCA) - 5% of cases in patients >50 years 4
- Ocular vascular disease
- Susac syndrome (in younger patients with hearing loss and CNS lesions) 1
- MOGAD-associated optic neuritis (if painful) 3
Diagnostic Work-Up
Triage immediately to the nearest emergency department or stroke center 1. The evaluation must be urgent because stroke risk may be as high as 25% in newly diagnosed cases 1.
Immediate Assessment:
For patients ≥50 years old with any GCA symptoms:
- Immediate ESR, CRP, and CBC with platelets 1
- GCA symptoms include: headache, scalp/temporal tenderness, jaw claudication, malaise, fatigue, fever, diplopia, polymyalgia rheumatica history
Comprehensive Stroke Work-Up:
Vascular imaging (urgent):
- Carotid ultrasound or CT/MR angiography to identify high-grade stenosis (>75% diameter reduction) 1
- Look specifically for ulcerated plaques or hemodynamically significant stenoses
Cardiac evaluation:
- Transthoracic echocardiography to assess for cardioembolic sources 4
- Transesophageal echo if high suspicion and negative initial workup
- Ambulatory cardiac monitoring for atrial fibrillation detection (duration not yet defined but appropriate in all patients without clear alternative cause) 4
Laboratory studies:
- Antiphospholipid antibodies
- Hypercoagulable panel (especially in younger patients or unclear etiology)
- Autoimmune workup if indicated
Ophthalmologic examination:
- Funduscopic exam to rule out retinal emboli (Hollenhorst plaques)
- Rule out retinal detachment or intraocular hemorrhage
- Document visual acuity and visual fields
Age-Specific Considerations:
Recent evidence shows age significantly impacts differential diagnosis 5:
- Patients ≥50 years: Focus on atherosclerotic and embolic vascular etiologies
- Younger patients: Consider Susac syndrome (with multiple/recurrent episodes), carotid dissection, hypercoagulable states, MOGAD (if painful)
Management
Acute Phase:
No proven acute intervention exists for amaurosis fugax itself, as vision typically returns spontaneously. However, the focus is on preventing permanent vision loss and stroke.
Secondary Prevention:
The management strategy depends on identified etiology 4:
For atherosclerotic/cryptogenic causes:
- Antiplatelet therapy: Aspirin 81 mg daily or clopidogrel 75 mg daily 4
- Consider dual antiplatelet therapy for 21 days (aspirin + ticagrelor or clopidogrel) if treating as minor stroke equivalent, followed by single agent 4
- High-intensity statin therapy
- Aggressive risk factor modification: hypertension control, diabetes management, smoking cessation, lipid management
For carotid stenosis:
- Symptomatic high-grade stenosis (>70%): Carotid endarterectomy or stenting 4
- Historical data shows operated patients had 6.4% cumulative morbidity versus 21.9% in non-operated patients (p=0.02) 6
- Decision between surgical revascularization versus medical management depends on surgical risk
For atrial fibrillation or cardioembolic source:
- Oral anticoagulation per stroke prevention guidelines 4
- Classify amaurosis fugax as stroke when calculating CHA₂DS₂-VASc score 4
For GCA:
- Immediate high-dose systemic corticosteroids (before biopsy if high suspicion)
- Monitor glucose carefully in diabetic patients
Collaborative Care:
Secondary prevention requires coordination between neurology, ophthalmology, and primary care 4. Recent data shows that despite similar vascular burden between amaurosis fugax and permanent retinal artery occlusion patients, AF patients received vascular interventions more frequently 7, suggesting potential treatment disparities.
Prognosis
The natural history data reveals:
- Annual stroke risk: 2% 8
- Annual risk of permanent monocular blindness: 1% 8
- Myocardial infarction risk: 30% 8
- 18% mortality rate (likely cardiovascular) 8
Recent cohort data shows 8.8% recurrence rate (either new amaurosis fugax or cerebral infarction) over median 3.5-year follow-up 2. Patients with "other determined cause" (TOAST-OC) etiology had highest recurrence risk (HR=9.66), as did those with prior ischemic stroke history (HR=4.21) 2.
Notably, in two-thirds of patients, the cause remains undetermined despite thorough workup 2, emphasizing the importance of aggressive risk factor modification regardless of identified etiology.
Critical Pitfalls to Avoid:
- Do not dismiss as benign: Amaurosis fugax is a harbinger of stroke and permanent blindness 6
- Do not delay evaluation: Time-sensitive workup is essential
- Do not miss GCA: Always screen patients ≥50 years for arteritic symptoms
- Do not forget cardiac monitoring: AF detection changes management to anticoagulation
- Do not overlook painful episodes: Consider MOGAD rather than vascular causes 3